ARA-290 (Cibinetide): A Literature Course in Six Modules

ARA-290 — also written ARA 290 and referred to as cibinetide in later publications — appears in the peer-reviewed record as a short, engineered peptide derived from erythropoietin (EPO) that was designed to retain tissue-protective signalling without stimulating red blood cell production, a design the authors of one in vitro study described directly in the phrase "engineered non-erythropoietic erythropoietin-derived peptide" (PMID 32335150). This course organises the published literature into six modules so that a reader can see what was studied, in what model, and with what reported endpoints.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or decision. Nothing below is a protocol, a schedule, or a suggestion to use anything. Where a study reported an outcome, that outcome belongs to that study and its model — not to any individual reader.

How this course is organised

1. Module 1 — what ARA-290 is and how it has been studied: definition, class, origin, forms.
2. Module 2 — mechanism as described in the literature.
3. Module 3 — reported outcomes by study: models, endpoints, results.
4. Module 4 — ARA-290 side effects: what studies report.
5. Module 5 — pharmacokinetics, where data exist.
6. Module 6 — regulatory status, stated factually.

Every module closes with the limits of its own evidence, because the ARA-290 literature is small, model-heavy, and dominated by early-phase or exploratory work.

Module 1: What ARA-290 Is and How It Has Been Studied

Definition and class

In the published work, ARA-290 is classed as a peptide — not a small molecule and not a full protein — engineered from erythropoietin. One rodent pain paper described it in its title as "a peptide derived from the tertiary structure of erythropoietin," which is the origin story most papers repeat: the sequence was taken from a surface region of the folded EPO molecule rather than from the part responsible for erythropoiesis (PMID 24529189). A transplantation study labelled the same compound "a nonhematopoietic erythropoietin analogue," underlining that the intended distinction from EPO is the absence of blood-cell stimulation (PMID 26683514).

Naming and forms in the literature

Readers searching the record will meet the same molecule under several labels. Earlier papers used ARA 290 or ARA-290; later work, particularly the immunology and wound-healing literature, used the international non-proprietary name cibinetide, as in a colitis study whose title reported that "cibinetide dampens innate immune cell functions" (PMID 29026145). A separate radiochemistry group prepared a chelator-conjugated, technetium-99m-labelled version, 99mTc-DOTA-ARA-290, and evaluated it as a candidate SPECT imaging tracer rather than as a therapeutic (PMID 35317117).

How it has been studied

The ARA-290 evidence base can be grouped into four tiers. First, cell-based work: researchers reported that the peptide attenuated doxorubicin-induced genotoxicity and oxidative stress in an in vitro system (PMID 32335150). Second, animal models covering neuropathic pain (PMID 24529189), pathophysiological pain and TRPV1 signalling (PMID 26774587), experimental colitis (PMID 29026145), impaired wound healing in mice with genetic diabetes (PMID 29223734), islet transplantation (PMID 26683514) and Alzheimer-like pathology in mice (PMID 34343617). Third, small human studies: a randomized, double-blind pilot study in sarcoidosis patients with symptoms of small fiber neuropathy (PMID 23168581), a follow-on report in sarcoidosis-associated small nerve fiber loss (PMID 24136731) and a study in patients with type 2 diabetes (PMID 25387363). Fourth, narrative review and commentary, such as an expert-opinion article on ARA 290 for small fiber neuropathy in sarcoidosis (PMID 24555851).

Limits of the evidence in Module 1

The identity and classification of ARA-290 are consistent across papers, but "studied" is not the same as "established." The human record consists of small, early-phase investigations in narrow patient populations; the preclinical record is spread thinly across many different disease models with few replications by independent groups. No paper in this set is a large confirmatory trial, and no paper describes long-term human follow-up.

Module 2: Mechanism as Described in the Literature

The proposed receptor

The mechanistic claim made most explicitly in the literature is that the peptide acts through a receptor complex distinct from the classical EPO receptor. A murine wound-healing study stated in its title that activation of the EPOR–β common receptor complex by cibinetide ameliorated impaired healing in mice with genetic diabetes, which frames the target as a heterocomplex rather than the erythropoietic receptor alone (PMID 29223734). This proposed separation of receptors is the stated rationale for why the peptide was engineered to be non-erythropoietic (PMID 26683514).

Innate immune modulation

Several groups described the downstream effect as dampening of innate immune activation rather than broad immunosuppression. In a transplantation model, the study reported that the analogue inhibited macrophage activation and prevented damage to transplanted islets (PMID 26683514). In experimental colitis, researchers reported that cibinetide dampened innate immune cell functions and that the course of the model disease was ameliorated (PMID 29026145). In a mouse model of Alzheimer-like pathology, the study framed the mechanism as early monocyte modulation and reported that pathology progression decelerated (PMID 34343617).

Nociceptive and glial signalling

Two rodent pain papers described neural mechanisms. One reported that ARA 290 relieved pathophysiological pain by targeting the TRPV1 channel and positioned the finding as integration between the immune system and nociception (PMID 26774587). The other reported long-term relief of neuropathic pain coupled with suppression of the spinal microglia response, linking the behavioural readout to glial activity in the spinal cord (PMID 24529189).

Oxidative and genotoxic stress

A cell-based toxicology study added a fourth mechanistic thread, reporting that the peptide attenuated doxorubicin-induced genotoxicity and oxidative stress in vitro (PMID 32335150).

Limits of the evidence in Module 2

Mechanism in this literature is inferred from models. Receptor-level claims rest largely on animal and cell systems; none of these papers demonstrates the proposed receptor pathway in human tissue as a clinical endpoint. Mechanistic plausibility across pain, immunity and oxidative stress does not establish that any one pathway drives any human outcome, and the diversity of proposed mechanisms is itself a sign that the pathway is not fully resolved.

Module 3: Reported Outcomes by Study

The table below summarises what each paper studied and what it reported. Each reported result carries its citation in the same cell.

Reading the outcome table without over-reading it

Two features of this table matter more than any individual row. First, the human rows are concentrated in two conditions — sarcoidosis-associated small fiber neuropathy and type 2 diabetes — and the sarcoidosis work was explicitly published as pilot-stage research (PMID 23168581), a framing an expert-opinion review of ARA 290 in sarcoidosis also adopted (PMID 24555851). Second, the preclinical rows each represent a single disease model; a reported result in colitis mice (PMID 29026145) says nothing about human inflammatory bowel disease, and a reported result in diabetic mouse wounds (PMID 29223734) says nothing about human wound care.

Limits of the evidence in Module 3

None of these reports should be read as a benefit that transfers to people outside the studied populations. Pilot and early-phase studies are designed primarily to generate hypotheses and check feasibility; effect sizes from such studies frequently shrink or disappear in larger, better-powered replications. This course does not summarise any confirmatory phase 3 outcome for ARA-290, because none appears in the verified literature used here.

Module 4: ARA-290 Side Effects: What Studies Report

The tolerability record for ARA-290 comes almost entirely from the small human studies, and it is thin by design. The sarcoidosis pilot was structured as a safety and efficacy study in patients with symptoms of small fiber neuropathy, meaning tolerability was a stated objective rather than an afterthought (PMID 23168581). A subsequent clinical report in sarcoidosis-associated small nerve fiber loss continued dosing in patients while measuring symptoms and corneal nerve fiber density, and an expert-opinion review of that programme discussed ARA 290 as an investigational candidate under evaluation for this indication (PMID 24136731, PMID 24555851). A further clinical study extended human exposure to patients with type 2 diabetes and reported metabolic and neuropathic endpoints (PMID 25387363).

The erythropoiesis question

Because ARA-290 derives from erythropoietin, the most obvious theoretical hazard is the one EPO itself carries: stimulation of red cell production with downstream haematological effects. The literature addresses this in the compound's own name. Papers describe the peptide as "non-erythropoietic" (PMID 32335150) and as "a nonhematopoietic erythropoietin analogue" (PMID 26683514), reflecting the engineering intent to avoid that class of effect.

What is not in the record

Several things follow from how small this literature is. The verified papers summarised here do not provide a pooled adverse-event table, a long-term human safety dataset, immunogenicity surveillance over years, pregnancy or paediatric exposure data, or interaction studies with other medicines. Absence of reported adverse events in pilot-scale research is not the same as demonstrated safety: small studies cannot detect uncommon events, and rare harms typically surface only in larger or longer programmes.

Limits of the evidence in Module 4

Any tolerability impression drawn from this set is provisional and applies to the specific supervised clinical settings in which the peptide was administered — sarcoidosis small fiber neuropathy (PMID 23168581) and type 2 diabetes (PMID 25387363) — and not to unsupervised use of material obtained outside a clinical trial.

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetics is the weakest area of the publicly indexed ARA-290 record covered by this course. None of the verified papers is a dedicated human pharmacokinetic study reporting absorption, distribution, metabolism, elimination or half-life values; the clinical publications are framed around symptom and physiological endpoints instead (PMID 23168581, PMID 25387363).

The closest available distribution data

The nearest proxy for distribution data in this set is the radiochemistry work, in which researchers synthesised 99mTc-DOTA-ARA-290 and evaluated it as a potential SPECT tracer for targeting the cardiac ischemic region — a study design that depends on where a labelled peptide conjugate goes in the body (PMID 35317117). It is important to read that paper for what it is: the tracer is a chemically modified conjugate assessed for imaging, not the unmodified peptide assessed for therapeutic exposure.

What model routes imply — and do not

Preclinical studies administered the peptide in various animal models of pain, colitis, wound healing, transplantation and neurodegeneration (PMID 24529189, PMID 29026145, PMID 34343617). Animal exposure conditions do not translate directly into human pharmacokinetics, and this course deliberately states no dose figures, because dosing details are not the point of an educational summary and no quantity should be inferred from it.

Limits of the evidence in Module 5

With no dedicated human PK publication in this set, statements about how long ARA-290 persists, how it is cleared, or how exposure scales cannot be supported here. Readers who encounter confident half-life claims elsewhere should check whether a primary source is cited at all.

Module 6: Regulatory Status, Stated Factually

Several factual points can be stated without speculation. ARA-290 / cibinetide appears in the literature as an investigational peptide: the sarcoidosis programme was published as pilot-stage clinical research (PMID 23168581) and discussed in an Expert Opinion on Investigational Drugs review, a journal whose scope is candidate agents rather than marketed products (PMID 24555851).

• Approved products: none of the verified papers describes an approved ARA-290 medicine. Approved erythropoiesis-stimulating agents exist as separate, distinct products; ARA-290 was engineered specifically to lack that erythropoietic activity and is a different molecule (PMID 26683514).
• Research-use-only material: peptides distributed with "research use only" or "not for human consumption" labelling are not evaluated by regulators for human quality, purity, sterility or potency. Such labelling is a legal and manufacturing category, not a quality certificate, and it does not make a compound a medicine.
• Compounding: in the United States, compounded preparations are generally limited to substances that meet statutory criteria — for example appearing in an applicable FDA bulk drug substances category or being a component of an approved drug. A peptide without an approved product and without such listing does not automatically qualify for compounding, and rules change over time.
• Imaging conjugates: the radiolabelled 99mTc-DOTA-ARA-290 described in the literature was a laboratory tracer candidate under evaluation, not a marketed diagnostic (PMID 35317117).

This section describes general regulatory categories for educational purposes and is not legal advice; regulations differ by country and change over time, and anyone with a legal question should consult a qualified professional.

Limits of the evidence in Module 6

Regulatory status is a moving target and is jurisdiction-specific. A paper published years ago tells a reader what stage a programme had reached at that time, not what its status is today.

What the Studies Did Not Test

A fair reading of this literature is defined as much by absences as by findings. Across the verified papers, the studies did not test:

• Healthy-person use. The human studies enrolled patients with sarcoidosis-associated small fiber neuropathy (PMID 24136731) or type 2 diabetes (PMID 25387363), not healthy volunteers seeking enhancement.
• Long-term outcomes. No paper here reports multi-year human follow-up for efficacy or safety.
• Performance, body composition or longevity endpoints. None of the verified studies measured strength, athletic performance, fat loss or lifespan.
• Human replication of preclinical findings. The colitis, wound-healing, islet-transplantation, Alzheimer-model and doxorubicin findings (PMID 29026145, PMID 29223734, PMID 26683514, PMID 34343617, PMID 32335150) were not carried into confirmatory human trials within this set.
• Combinations. No study here evaluated ARA-290 alongside other peptides or supplements.
• Unregulated material. Every human result described above came from supervised clinical research using characterised study drug, not from self-obtained material of unknown composition.

Read as a whole, the ARA-290 literature is an early, mechanistically interesting body of work with consistent framing — a non-erythropoietic EPO-derived peptide acting on innate immune and nociceptive pathways — and a genuinely limited human evidence base. That combination is common for research peptides, and the honest summary is that researchers reported encouraging signals in small studies and specific models while the larger questions remain open.

References

• Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study (Molecular Medicine, 2012)
• ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (Molecular Medicine, 2013)
• ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response (Molecular Pain, 2014)
• ARA 290 for treatment of small fiber neuropathy in sarcoidosis (Expert Opinion on Investigational Drugs, 2014)
• ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes (Molecular Medicine, 2015)
• A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets (Transplantation, 2016)
• ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception (Peptides, 2016)
• Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis (Scientific Reports, 2017)
• Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes (Biochimica et Biophysica Acta: Molecular Basis of Disease, 2018)
• An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress (Toxicology in Vitro, 2020)
• Synthesis and evaluation of 99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region (Iranian Journal of Basic Medical Sciences, 2021)
• Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression (Brain, Behavior, and Immunity, 2022)